A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Avelumab (Primary) ; Tomivosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.